The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but doesn’t enhance the efficacy of doxorubicin, despite improving tumour perfusion and radiation response in mice
| Autor: | Ali, M., Kamjoo, M., Thomas, H. D., Kyle, S., Pavlovska, I., Babur, M., Telfer, B. A., Curtin, N. J., Williams, K. J. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Zdroj: | Molecular Cancer Therapeutics; Vol 10 |
| ISSN: | 1535-7163 |
| DOI: | 10.1158/1535-7163.mct-11-0356 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|